Lorbas, Cdiddy & others - Regarding need for a Phase III, sample sizes, other companies' Phase II successes & consequent PIII failures,etc. What I think is missing in this convo, is as Dr Patterson has said many times before, in the case of Leronlimab there is a direct link between what it is doing (and supposed to do) clinically and what the patients have been experiencing (i.e., we know why the drug works!). I don't think in the case of these other drugs that was the case and, that, is what is greatly in favor of Leon getting an EUA based on PII results.